Lactiplantibacillus plantarum WLPL04 from Human Breast Milk Attenuates Hyperuricemia via Coordinated Purine Salvage Pathway, Renal Transporter Regulation, and Gut Microbiota Remodeling
Nutrients · 31.10.2025 · 17 (21) · 3447
DOI: 10.3390/nu17213447 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, online erschienen am 31.10.2025. Verfasst von Min Wei und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang 330047, China. Hauptthemen laut MEDLINE: Hyperuricemia, Gastrointestinal Microbiome, Milk, Human, Purines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangxi.
Abstract (Originalsprache)
Background
Hyperuricemia (HUA), a metabolic disorder characterized by high serum uric acid (UA) level, presents a growing global health challenge.
Method
In this study, a stable murine model of HUA was established by orally administering adenine (100 mg/kg) and potassium oxonate (600 mg/kg) in C57BL/6J mice, resulting in significant elevation of serum UA and xanthine oxidase (XOD) activity, as well as renal pathological alterations. Given the anti-hyperuricemia potential of Lactiplantibacillus plantarum WLPL04, a strain from a human breast milk was evaluated.
Conclusions
Oral administration of L. plantarum WLPL04 significantly reduced serum UA level and XOD activity in a dose-dependent manner. Moreover, L. plantarum WLPL04 treatment enhanced UA excretion by upregulating ABCG2 and downregulating URAT1 and GLUT9 expression. It ameliorated renal injury and suppressed inflammation via downregulation of the NLRP3 inflammasome pathway. 16S rRNA gene sequencing revealed that L. plantarum WLPL04 restored gut microbial diversity and promoted the enrichment of beneficial genera such as Bacteroides, which was negatively correlated with UA in serum, creatinine, and inflammatory cytokines. Moreover, transcript analysis revealed upregulation of purine salvage genes (hpt and xpt), suggesting enhanced salvage pathway recycling of purine bases and reduced urate production. Those findings suggest that L. plantarum WLPL04 exerted multi-targeted anti-hyperuricemia effects through coordinated regulation of host purine metabolism, urate transport, inflammation, and gut microbiota composition, providing a promising probiotic candidate for HUA management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang 330047, China.
- International Institute of Food Innovation Co., Ltd., Nanchang University, Nanchang 330047, China.
- Centre for Translational Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang 330047, China.
ORCID-Profile: Zhihong Zhang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangxi
Zitieren
APA
Wei, M., Hu, Y., Zhang, Z., Qiu, L., Tao, X., & Wei, H. (2025). Lactiplantibacillus plantarum WLPL04 from Human Breast Milk Attenuates Hyperuricemia via Coordinated Purine Salvage Pathway, Renal Transporter Regulation, and Gut Microbiota Remodeling. Nutrients, 17(21), 3447. https://doi.org/10.3390/nu17213447
Vancouver
Wei M, Hu Y, Zhang Z, Qiu L, Tao X, Wei H. Lactiplantibacillus plantarum WLPL04 from Human Breast Milk Attenuates Hyperuricemia via Coordinated Purine Salvage Pathway, Renal Transporter Regulation, and Gut Microbiota Remodeling. Nutrients. 2025;17(21):3447. doi:10.3390/nu17213447
BibTeX
@article{Wei2025,
author = {Wei, Min and Hu, Yingsheng and Zhang, Zhihong and Qiu, Liang and Tao, Xueying and Wei, Hua},
title = {Lactiplantibacillus plantarum WLPL04 from Human Breast Milk Attenuates Hyperuricemia via Coordinated Purine Salvage Pathway, Renal Transporter Regulation, and Gut Microbiota Remodeling},
journal = {Nutrients},
year = {2025},
volume = {17},
number = {21},
pages = {3447},
doi = {10.3390/nu17213447}
}
EUVIMED